Media stories about KalVista Pharmaceuticals (NASDAQ:KALV) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 47.8513883523043 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
KALV has been the topic of a number of research reports. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 target price on the stock. ValuEngine raised shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd.
KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The firm had revenue of $0.10 million for the quarter. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 60.42%.
In other news, major shareholder Holdings A/S Novo sold 176,647 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $7.21, for a total value of $1,273,624.87. Following the transaction, the insider now owns 2,876,027 shares in the company, valued at $20,736,154.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 212,547 shares of company stock worth $1,561,843 in the last 90 days. Company insiders own 49.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “KalVista Pharmaceuticals (KALV) Given Daily News Impact Rating of 0.11” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/09/26/kalvista-pharmaceuticals-kalv-given-daily-news-impact-rating-of-0-11.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.